NCT07152873尚未招募1 期
An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and the Pharmacokinetics of AD-117 Compared to AD-117A in Healthy Adult Volunteers Under Fed State Conditions
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Maximum concentration of drug in plasma (Cmax)
研究概览
简要总结
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-117 in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Body weight equal to or greater than 50kg (Female 45kg) and Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit
- •The Age equal to or greater than 19 in healthy volunteers at the time of screening visit
排除标准
- •Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
- •Other exclusions applied
研究组 & 干预措施
Sequence B (TR)
Experimental
Period 1: Test (AD-117), Period 2: Reference (AD-117A)
干预措施: AD-117 (Drug)
Sequence B (TR)
Experimental
Period 1: Test (AD-117), Period 2: Reference (AD-117A)
干预措施: AD-117A (Drug)
Sequence A (RT)
Experimental
Period 1: Reference (AD-117A), Period 2: Test (AD-117)
干预措施: AD-117 (Drug)
Sequence A (RT)
Experimental
Period 1: Reference (AD-117A), Period 2: Test (AD-117)
干预措施: AD-117A (Drug)
结局指标
主要结局
Maximum concentration of drug in plasma (Cmax)
时间窗: pre-dose (0hour) to 72hours
Cmax of AD-117
Area under the plasma concentration-time curve during dosing interval (AUCt)
时间窗: pre-dose (0hour) to 72hours
AUCt of AD-117
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227BNCT06884085Addpharma Inc.70
已完成
1 期
A Study to Evaluate the Safety and Pharmacokinetics of AD-221 Compared to Coadministration of AD-221A and AD-221BHyperlipidemiasNCT05202405Addpharma Inc.64
已完成
1 期
A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091Embolism and ThrombosisNCT05128591Addpharma Inc.38
已完成
1 期
Evaluating the Pharmacokinetic Characteristics of AD-102 in Healthy VolunteersOsteoporosisNCT03824171Addpharma Inc.52
已完成
1 期
A Study to Evaluate the Safety and Pharmacokinetics of AD-228A Compared to Coadministration of AD-2281 and AD-2282NCT06858865Addpharma Inc.60